Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-Df-IAB2M Imaging in Localized Prostate Cancer
NCT03675451Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Feb 2017
- Primary completion
- Jun 2018
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
A Phase 2 trial of 89Zr-DF-IAB2M in prostate cancer (PCa), sponsored by Weill Cornell Medicine. Started Feb 2017; status: completed.
02
Drugs
89Zr-DF-IAB2M
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03675451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03675451.